非小细胞肺癌脑转移的放疗进展  

Progression of radiotherapy for brain metastases in non-small cell lung cancer

作　　者：纪环 周菊英[1] 马辰莺[1] 徐晓婷[1] 秦颂兵[1] Ji Huan;Zhou Juying;Ma Chenying;Xu Xiaoting;Qin Songbing(Department of Radiation Oncology,First Affiliated Hospitial of Soochow University,Suzhou 215006,China)

机构地区：[1]苏州大学附属第一医院放疗科,苏州215006

出　　处：《国际肿瘤学杂志》2022年第3期181-184,共4页Journal of International Oncology

摘　　要：脑转移是非小细胞肺癌(NSCLC)患者最常见的远处转移之一, 且预后差。化疗、手术对其治疗效果有限。放疗作为标准治疗方式, 广泛地应用于临床实践中。单纯放疗包括全脑放疗、立体定向放疗以及全脑放疗联合立体定向放疗。随着放疗的不断发展以及基因测序的进步, 放疗现已与靶向药物、抗血管生成药物、免疫药物联合应用在NSCLC脑转移的治疗中, 可改善NSCLC脑转移患者的生存。Brain metastases are one of the most common distant metastases in patients with non-small cell lung cancer(NSCLC),and the prognosis will be extremely poor.The effect of chemotherapy and operation is limited.As a standard treatment,radiotherapy is widely used in clinical practice.Radiotherapy alone includes whole brain radiotherapy,stereotactic radiotherapy and whole brain radiotherapy combined with stereotactic radiotherapy.With the continuous development of radiotherapy and the progress of gene sequencing,radiotherapy has been combined with targeted drugs,anti-angiogenic drugs and immunodrugs in the treatment of NSCLC brain metastasis,which can improve the survival of patients with NSCLC brain metastasis.

关 键 词：癌 非小细胞肺 脑转移 放射治疗 靶向治疗 抗血管生成治疗 

分 类 号：R734.2[医药卫生—肿瘤]